Stocks to Watch today, May 7, 2026: Mahindra Lifespaces, Deepak Fertilizers, Newgen Software, and Pidilite Industries are among the top stocks to watch today
The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.
Biocon founder Kiran Mazumdar-Shaw outlines a five-year transition plan, naming niece Claire Mazumdar as successor to lead the company's next growth phase
Claire Mazumdar, founding CEO of Bicara Therapeutics, has been named as successor to Biocon founder Kiran Mazumdar-Shaw, with a gradual leadership transition planned.
She plans a gradual leadership transition over the next five years, with her niece Claire Mazumdar expected to assume the chair in a phased manner
Stocks to Watch today, April 8, 2026: Banks, Real estate, automobiles, Infosys, Aurobindo Pharma are some of the key stocks to watch today
According to Bloomberg, 3.19 million shares were traded in multiple block deals. Buyers and sellers of the transactions were not known
Company plans to leverage capacity gaps and pricing dynamics in insulin as global pharma majors shift focus to GLP-1 therapies amid rising diabetes burden
Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.
Nifty Pharma index today: The Trump administration may announce new tariffs on drugmakers that have not struck deals guaranteeing low prices in the country
Biocon Limited names Shreehas Tambe CEO, outlines AI-led, integration-driven strategy to boost global biosimilars and generics growth
Biocon Ltd on Friday said it has appointed Shreehas Tambe as CEO & Managing Director, effective April 1, 2026. As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilars and generics, strengthening the company's ability to operate at scale and compete effectively in global markets, the company said in a statement. Further, Kedar Upadhye has also been appointed as Chief Financial Officer, Biocon said. This leadership transition is part of the full integration of Biocon Biologics Ltd as a wholly-owned subsidiary of Biocon Ltd, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies, the company said. Commenting on the development, Biocon Ltd Executive Chairperson, Kiran Mazumdar-Shaw said the company has consistently grown by .